Unprecedented advances have been made in cancer treatment with the use of immune
checkpoint blockade (ICB). However, responses are limited to a subset of patients, and�…

Immune checkpoint blockade (ICB) has rapidly transformed the treatment paradigm for
various cancer types. Multiple single or combinations of ICB treatments have been approved�…

Targeted immune checkpoint blockade augments anti-tumor immunity and induces durable
responses in patients with melanoma and other solid tumors. It also induces specific�…

Despite decades of clinical and preclinical studies, the markers and mechanisms of
resistance to cancer immunotherapy, particularly immune checkpoint blockade (ICB), remain�…

The emergence of immune checkpoint blockade therapies over the last decade has
transformed cancer treatment in a wide range of tumor types. Unprecedented and durable�…

Unprecedented advances have been made in the treatment of cancer through the use of
immune checkpoint blockade, with approval of several checkpoint blockade regimens�…

Immune checkpoint blockade therapy (ICBT), which blocks negative immune-activating
signals and maintains the antitumor response, has elicited a remarkable clinical response in�…

Immune checkpoint therapy (ICT) has dramatically altered clinical outcomes for cancer
patients and conferred durable clinical benefits, including cure in a subset of patients�…

Immune checkpoint therapy (ICT) can provide durable clinical responses and improve
overall survival. However, only subsets of patients with specific tumor types respond to ICT�…

Immune checkpoint inhibitors (ICIs) have made an indelible mark in the field of cancer
immunotherapy. Starting with the approval of anti-cytotoxic T lymphocyte-associated protein�…